[CAS NO. ] Ieramilimab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Catalog

HY-P99027

Brand

MCE

CAS

-

DESCRIPTION

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Ieramilimab]

For research use only. We do not sell to patients.

Summary

Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3 , resulting in inhibition of LAG-3 interaction with MHC-II molecules ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03484923	Novartis Pharmaceuticals\|Novartis	Melanoma	September 10, 2018	Phase 2
NCT02460224	Novartis Pharmaceuticals\|Novartis	Advanced Solid Tumors	June 17, 2015	Phase 1\|Phase 2
NCT03742349	Novartis Pharmaceuticals\|Novartis	Triple Negative Breast Cancer (TNBC)	January 31, 2019	Phase 1
NCT03365791	Novartis Pharmaceuticals\|Novartis	Small Cell Lung Cancer\|Gastric Adenocarcinoma\|Esophageal Adenocarcinoma\|Castration Resistant Prostate Adenocarcinoma\|Soft Tissue Sarcoma\|Ovarian Adenocarcinoma\|Advanced Well-differentiated Neuroendocrine Tumors\|Diffuse Large B Cell Lymphoma	January 24, 2018	Phase 2
NCT03499899	Novartis Pharmaceuticals\|Novartis	Triple-negative Breast Cancer	July 2, 2018	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Patrick Schöffski, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022 Feb;10(2):e003776.